John Chiplin
NON-EXECUTIVE DIRECTOR
Healthcare
BioMolTech
New Zealand
Biography
John has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions in which John has been instrumental include Benitec BioPharma (US IPO), Medistem (acquired by Intrexon Corporation for US$26 million), former CEO of ASX-listed Arana Therapeutics (acquired by Cephalon Inc. for US$200 million), and Domantis (acquired by GSK for £230 million). Immediately prior to running Arana, John was head of the ITI Life Sciences investment fund in the UK, negotiating significant funding with Government Ministers. His own investment company, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. John’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on the boards of Batu Biologics, Benitec BioPharma (NASDAQ:BNTC), The Coma Research Institute, Cynata Therapeutics (ASX:CYN), Prophecy Inc, Scancell Holdings plc (LSE:SCLP), and ScienceMedia Inc.
Research Interest
John has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions in which John has been instrumental include Benitec BioPharma (US IPO), Medistem (acquired by Intrexon Corporation for US$26 million), former CEO of ASX-listed Arana Therapeutics (acquired by Cephalon Inc. for US$200 million), and Domantis (acquired by GSK for £230 million). Immediately prior to running Arana, John was head of the ITI Life Sciences investment fund in the UK, negotiating significant funding with Government Ministers. His own investment company, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. John’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on the boards of Batu Biologics, Benitec BioPharma (NASDAQ:BNTC), The Coma Research Institute, Cynata Therapeutics (ASX:CYN), Prophecy Inc, Scancell Holdings plc (LSE:SCLP), and ScienceMedia Inc.
